HBC(SH:603077) Xin Lang Cai Jing·2026-01-23 05:47Core Viewpoint - The stock of Hebang Biotechnology has shown significant price increases recently, with a year-to-date rise of 17.70% and a 19.82% increase over the past five trading days, indicating strong market interest despite a decline in revenue and profit [1][2]. Company Overview - Hebang Biotechnology, established on August 1, 2002, and listed on July 31, 2012, is located in Leshan, Sichuan Province. The company specializes in the manufacturing of pesticides and intermediates, fine chemicals, intelligent glass, special glass, and the development of soda ash, ammonium chloride, and mineral resources [1]. - The company's revenue composition includes 85.89% from chemical products, 17.61% from photovoltaic glass and other products, 6.74% from mineral products, and 5.02% from other businesses [1]. Financial Performance - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.927 billion yuan, a year-on-year decrease of 13.02%. The net profit attributable to shareholders was 93.1085 million yuan, down 57.93% compared to the previous year [2]. - The company has distributed a total of 1.205 billion yuan in dividends since its A-share listing, with 553 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period. The average number of circulating shares per person increased by 2.03% to 44,939 shares [2]. - Among the top ten circulating shareholders, notable changes include the entry of new shareholders such as Penghua Zhongzheng Segmented Chemical Industry Theme ETF and the increase in holdings by Hong Kong Central Clearing Limited [3].